What is HALO Pharmaceutical?
HALO Pharmaceutical operates as a contract development and manufacturing organization (CDMO), offering comprehensive scientific, regulatory, and development expertise. The company specializes in assisting clients in bringing their products to market efficiently and within budget. HALO provides integrated capabilities across a wide array of dosage forms, including tablets, capsules, powders, liquids, creams, and sterile/non-sterile ointments and suppositories, catering to CI-CV designations. Their services span tech transfer, process and product development, production, scale-up, validation, and analytical method development, enabling partnerships from early-stage development through commercialization.
How much funding has HALO Pharmaceutical raised?
HALO Pharmaceutical has raised a total of $25M across 1 funding round:
Other Financing Round
$25M
Other Financing Round (2025): $25M with participation from Noramco
Key Investors in HALO Pharmaceutical
Noramco
Noramco is a leading North American producer of controlled substances bulk Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, focusing on APIs for abuse prevention, pain management, and addiction management.
What's next for HALO Pharmaceutical?
The recent major strategic investment signals a period of accelerated growth and expansion for HALO Pharmaceutical. This capital is likely to be deployed towards enhancing manufacturing capacities, expanding technological capabilities, and potentially broadening its service offerings to meet the increasing demand for specialized CDMO services. The company is well-positioned to leverage this financing to solidify its market presence and pursue new strategic partnerships within the pharmaceutical industry, aiming to further streamline the drug development and commercialization process for its clients.
See full HALO Pharmaceutical company page
